The Future In Our Hands: Screening For Preclinical Alzheimer's Disease By Analysing Hand Movements
Funder
National Health and Medical Research Council
Funding Amount
$899,782.00
Summary
Alzheimer's disease (AD) starts damaging the brain 10-20 years before memory problems begin. By the time of diagnosis, it is hard to treat because the damage is so severe. We need a way to detect AD much earlier. We will develop a simple new computer test to detect early signs of AD by recording and analysing hand movements. Then people can start prevention earlier and scientists can research better treatments to improve people's quality of life and reduce the number of people with dementia.
Genetic Investigations For Prodromal Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$719,374.00
Summary
The disease process in Alzheimer’s disease (AD) begins decades before a diagnosis is made. We urgently need to investigate this pre-symptomatic stage to learn how the disease process begins, and allow the development of treatments that work before the brain is irreparably damaged. I will use genetic risk factors for AD to predict who is most at risk of developing AD. I will look for early changes and easily accessible markers, including the use of state of the art brain imaging.
Element Labeling Antibodies For Bio-imaging Of Proteins: A Case Study Of Beta-amyloid In Alzheimer's Disease Mouse Models
Funder
National Health and Medical Research Council
Funding Amount
$221,136.00
Summary
This project will develop new analytical methods for quantitative in-situ imaging of beta-amyloid in mouse brains. Beta-amyloid deposition in the brain is associated with Alzheimer�s disease. It is also planned to simultaneously image metal ions, which are also implicated in the deposition of beta-amyloid. Application of these novel methods to Alzheimer�s disease mouse models will provide new knowledge and significant insights into the aetiology of Alzheimer�s disease by determining the relation ....This project will develop new analytical methods for quantitative in-situ imaging of beta-amyloid in mouse brains. Beta-amyloid deposition in the brain is associated with Alzheimer�s disease. It is also planned to simultaneously image metal ions, which are also implicated in the deposition of beta-amyloid. Application of these novel methods to Alzheimer�s disease mouse models will provide new knowledge and significant insights into the aetiology of Alzheimer�s disease by determining the relationship between amyloid proteins and metal ions.Read moreRead less
A New Approach To Explore The Role Of Selenoproteins In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$374,284.00
Summary
Selenoproteins play an important role in a variety of major diseases. Yet knowledge of the biology of selenium and its role in disease prevention and progression is not sufficient to recommend selenium supplementation for disease prevention or treatment. The broad aim of this research is to identify and characterise the response of selenoproteins to selenium supplementation and disease states.
The Role Of Peripheral Blood MicroRNAs As Biomarkers Of Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$83,284.00
Summary
To investigate the role of microRNAs as biomarkers for Alzheimer's disease (AD) to allow for early diagnosis prior to the onset of clinically apparent memory decline. MicroRNA expression levels in blood samples from patients with AD, mild cognitive impairment and normal cognition will be assessed in order to determine potential biomarker candidates.
Unraveling The Molecular Mechanism Of Tau Spread In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,252,244.00
Summary
Disease progression in Alzheimer's disease is still poorly understood. The project is based on new findings by the research team that suggest that core cellular pathways and building blocks of nerve cell connections are required to allow the spread of pathology in the brain. This project will establish whether these pathways can be used as effective targets to intercept disease progression and prevent further cognitive decline in Alzheimer's disease pathology.
GloBal RetinAl Imaging CoNSorTium FOR AzheiMer's Disease (BRAINSTORM)
Funder
National Health and Medical Research Council
Funding Amount
$393,099.00
Summary
The retina of the eye displays features of Alzheimer's disease (AD). We have developed a new way to take photos of the eye with a rainbow-coloured flash to detect signs of AD. We now want to test how this and other eye imaging methods compare with brain scans and spinal fluid tests to identify people who are at risk of AD. We will use clinical studies, artificial intelligence, mouse models of AD and donated human tissues to achieve our aims. Our goal is to improve AD detection and care.
A Novel Intracellular Roadblock To Cobalamin Utilization In Ageing And Alzheimer�s Disease
Funder
National Health and Medical Research Council
Funding Amount
$11,304.00
Summary
Vitamin B12 is required for red blood cell formation, DNA synthesis and normal neurological function. B12 deficiency contributes to age-related cognitive decline and Alzheimer�s disease. This research will provide important new information regarding the ageing process and the impact that brain changes associated with ageing and Alzheimer's disease have on B12 metabolism. It will provide important information related to the therapeutic potential of B12.
Disentangling Aphasic Syndromes In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$682,936.00
Summary
Alzheimer’s disease, the main cause of disability in older Australians, can present with diverse and complex manifestations. Language disturbances are not entirely characterised and raises diagnostic difficulties. By development of novel clinical tools and cutting-edge structural brain imaging, this project aims to refine the spectrum of language disturbances, analyse the pattern of brain atrophy and investigate susceptibility factors across Alzheimer's presentations.